Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an Anti- avb3 Integrin Cytotoxin, in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer.

This document provides information about a clinical trial for a drug called ProAgio in the treatment of metastatic breast cancer. The trial is not yet recruiting participants and aims to enroll 51 adults with specific characteristics of breast cancer. The trial will assess the safety and efficacy of ProAgio in combination with Gemcitabine. The document also includes administrative information about the trial, such as contact details and collaborators. [Extracted from the article]